LONA

Business Context and Reporting Period

Company: Athira Pharma, Inc. (Note: Input metadata referenced "Leonabio," but the filing text identifies the registrant as Athira Pharma, Inc., trading under symbol ATHA).

Reporting Period: Quarter ended March 31, 2025.

Business Overview: Athira is a clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration. The company's lead drug candidate is ATH-1105, currently in development for Amyotrophic Lateral Sclerosis (ALS). Following the failure of its previous lead candidate, fosgonimeton, to meet primary endpoints in the LIFT-AD Phase 2/3 trial in September 2024, the company paused fosgonimeton development and shifted focus to ATH-1105. The company is currently exploring strategic alternatives, including potential mergers, acquisitions, or asset sales, to maximize stockholder value.

Key Financial Metrics

Liquidity: As of March 31, 2025, the company held $36.7 million in cash, cash equivalents, and short-term investments. Management estimates these funds are sufficient to finance operations for at least the next 12 months.

Material Changes vs. Prior Period

• Significant Reduction in Net Loss: Net loss decreased by approximately 65% (from $26.3 million to $9.1 million) compared to Q1 2024. This improvement is primarily driven by a 66% reduction in total operating expenses.
• R&D Expense Decline: R&D expenses dropped 80% (from $21.2 million to $4.3 million). This was largely due to a $13.0 million decrease in costs associated with the fosgonimeton program following the completion of the LIFT-AD trial and the decision to pause its development. This decrease was partially offset by $0.9 million in new costs for the ATH-1105 program.
• G&A Expense Decline: G&A expenses decreased 19% (from $6.5 million to $5.2 million), primarily due to reduced personnel-related expenses following a workforce reduction (Restructuring) initiated in September 2024, which terminated approximately 70% of the workforce.
• Cash Position: Cash and investments decreased by approximately $41.8 million from the beginning of the year to March 31, 2025, reflecting ongoing operational burn and net cash used in investing activities ($7.4 million) due to the purchase of available-for-sale securities.

Guidance, Outlook, and Risks

Outlook and Strategic Review: The company is actively exploring strategic alternatives to maximize stockholder value, including potential mergers, acquisitions, or asset sales. There is no assurance that a transaction will be completed. The company expects to continue incurring operating losses for the foreseeable future as it advances ATH-1105.

Nasdaq Listing Status: The company's common stock was transferred from the Nasdaq Global Market to the Nasdaq Capital Market on April 17, 2025. This transfer granted an additional 180-day grace period (until October 13, 2025) to regain compliance with the $1.00 minimum closing bid price requirement. The company is considering a reverse stock split to address this.

Key Risks:

• Capital Requirements: Substantial additional funding will be required to complete the development and commercialization of ATH-1105. Failure to raise capital could force the company to delay or terminate operations.
• Clinical Development Risk: ATH-1105 is in early clinical stages. There is no guarantee that future trials will demonstrate safety or efficacy, or that regulatory approval will be obtained.
• Strategic Transaction Uncertainty: The ongoing review of strategic alternatives is costly and time-consuming, with no guarantee of a successful outcome.
• Intellectual Property: The company relies on in-licensed patents (e.g., from Washington State University) and faces risks regarding the scope and validity of its IP portfolio.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $36.7 million cash balance against the current burn rate and the timeline for the strategic review process.
• Strategic Alternatives: Monitor for updates on the strategic review process, including any definitive agreements for mergers, acquisitions, or asset sales.
• Nasdaq Compliance: Track the stock price relative to the $1.00 minimum bid requirement and the status of the proposed reverse stock split authorization.
• ATH-1105 Progress: Review upcoming clinical trial data readouts for ATH-1105 in ALS to assess the viability of the company's sole remaining clinical asset.
• Legal Proceedings: Monitor the status of the Washington State University review regarding prior claims of research misconduct involving the former CEO, which could impact IP rights.